{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:14:17Z","timestamp":1793247257714,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13805-7","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:44:40Z","timestamp":1754109880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Acceptability of long acting injectable antiretroviral therapy in people living with HIV at a large single centre"],"prefix":"10.1038","volume":"15","author":[{"given":"Stefania","family":"Arsuffi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Mazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Calza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Riccardo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Minisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Fioretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itala","family":"Polesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Anzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Quiros-Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Foc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"13805_CR1","unstructured":"Agenzia Italiana del Farmaco. Ema raccomanda La Prima Terapia antiretrovirale iniettabile a lunga durata d\u2019azione per l\u2019hiv. (2020). https:\/\/www.aifa.gov.it\/-\/ema-raccomanda-la-prima-terapia-antiretrovirale-iniettabile-a-lunga-durata-d-azione-per-l-hiv"},{"key":"13805_CR2","unstructured":"European Medicines Agency. First long-acting injectable antiretroviral therapy for HIV recommended approval. (2020). https:\/\/www.ema.europa.eu\/en\/news\/first-long-acting-injectable-antiretroviral-therapy-hiv-recommended-approval"},{"key":"13805_CR3","unstructured":"Agenzia Italiana del Farmaco. Rekambys-Riassunto delle caratteristiche del prodotto. (2023). https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_001306_049280_FI.pdf&retry=0&sys=m0b1l3"},{"key":"13805_CR4","unstructured":"Agenzia Italiana del Farmaco. Vocabria-Riassunto delle caratteristiche del prodotto. (2023). https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_004834_049281_RCP.pdf&retry=0&sys=m0b1l3"},{"key":"13805_CR5","doi-asserted-by":"crossref","unstructured":"Margolis, D. A. et al. Spreen WR E Team, LAI116482 Study. Cabotegravir Plus Rilpivirine, once a Day, after Induction with Cabotegravir Plus Nucleoside Reverse Transcriptase Inhibitors in antiretroviral-naive Adults with HIV-1 Infection (LATTE): a Randomised, Phase 2b, dose-ranging Trial. Lancet Infect. Dis. (2015)","DOI":"10.1016\/S1473-3099(15)00152-8"},{"key":"13805_CR6","doi-asserted-by":"crossref","unstructured":"Margolis, D. A. et al. Willia. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet (2017)","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"13805_CR7","doi-asserted-by":"crossref","unstructured":"Jaeger, H. et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV (2021).","DOI":"10.1016\/S2352-3018(21)00185-5"},{"key":"13805_CR8","doi-asserted-by":"crossref","unstructured":"Orkin, C. et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV, (2021).","DOI":"10.1016\/S2352-3018(21)00184-3"},{"issue":"5","key":"13805_CR9","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3390\/ijerph21050602","volume":"21","author":"CK Campbell","year":"2024","unstructured":"Campbell, C. K. et al. LAI-ART awareness, willingness, barriers and facilitators among black sexual minority men living with HIV in the US South. Int. J. Environ. Res. Public. Health 21(5), 602. https:\/\/doi.org\/10.3390\/ijerph21050602 (2024).","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"13805_CR10","doi-asserted-by":"crossref","unstructured":"Dang, B. N. et al. Examining the link between patient satisfaction and adherence to HIV care: a structural equation model. PLoS One (2013).","DOI":"10.1371\/journal.pone.0054729"},{"key":"13805_CR11","doi-asserted-by":"crossref","unstructured":"Antela, A. et al. Patient-reported outcomes (PROs) in HIV infection: points to consider and challenges. Infect Dis Ther. 11(5):2017\u20132033.","DOI":"10.1007\/s40121-022-00678-w"},{"key":"13805_CR12","doi-asserted-by":"crossref","unstructured":"Lynda, C., Doward, S. P. & McKenna. Defining patient-reported outcomes. Value in Health (2004).","DOI":"10.1111\/j.1524-4733.2004.7s102.x"},{"key":"13805_CR13","doi-asserted-by":"crossref","unstructured":"Deshpande, P. R., Rajan, S., Sudeepthi, B. L. & Abdul Nazir, C. P. Patient-reported outcomes: a new era in clinical research. Perspect. Clin. Res. (2011).","DOI":"10.4103\/2229-3485.86879"},{"key":"13805_CR14","unstructured":"Valentina, M. et al. Use of long-acting therapies for HIV care in Italy: Are people living with HIV prepared for change? A cross-sectional study.\u00a0AIDS Patient Care and STDs (2022)."},{"key":"13805_CR15","doi-asserted-by":"crossref","unstructured":"Christia Palacios, C. et al. Expectations and acceptability of long-acting injectable antiretrovirals by patients living with HIV\/AIDS. Infect. Dis. 52,4 (2022)","DOI":"10.1016\/j.idnow.2022.01.010"},{"key":"13805_CR16","unstructured":"Sarah, E. et al. Acceptability and feasibility of long-acting injectable antiretroviral therapy for HIV-infected persons who inject drugs in Vietnam: A Qualitative Study. Lancet Regional Health - Western Pacific 1, (2023)."},{"key":"13805_CR17","unstructured":"Joseph, J. E. et al. Lenacapavir with bnabs GS-5423 and GS-2872 dosed every 6 months in people with HIV - croi conference, CROI Conference.. (2023). https:\/\/www.croiconference.org\/abstract\/lenacapavir-with-bnabs-gs-5423-and-gs-2872-dosed-every-6-months-in-people-with-hiv\/"},{"key":"13805_CR18","unstructured":"Office of the Commissioner. FDA approves new HIV drug for adults with limited treatment options. U.S. Food and Drug Administration. (2022). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-hiv-drug-adults-limited-treatment-options"},{"key":"13805_CR19","first-page":"8","volume":"5","author":"F Alberton","year":"2023","unstructured":"Alberton, F. et al. The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment. J Med Virol 5, 8 (2023).","journal-title":"J Med Virol"},{"key":"13805_CR20","unstructured":"Rusconi, S., Marcotullio, S. & Cingolani, A. Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient\u2019s perspective. New Microbiol. (2017)."},{"key":"13805_CR21","doi-asserted-by":"crossref","unstructured":"Simoni, J. M. et al. A conjoint analysis of the acceptability of targeted long-acting injectable antiretroviral therapy among persons living with HIV in the U.S. AIDS Behav, (2020).","DOI":"10.1007\/s10461-019-02701-7"},{"issue":"7","key":"13805_CR22","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1007\/s10461-024-04315-0","volume":"28","author":"XA Erguera","year":"2024","unstructured":"Erguera, X. A. et al. Acceptability of long-acting injectable antiretroviral therapy among people with HIV receiving care at three Ryan white funded clinics in the united States. AIDS Behav. 28(7), 2226\u20132238 (2024).","journal-title":"AIDS Behav."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13805-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13805-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13805-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:40:51Z","timestamp":1757331651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13805-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13805"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13805-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"28212"}}